From DNA to IND in as little as 6 months

Explore how innovative CMC strategies are transforming early antibody development. Learn how an integrated approach can accelerate the path from DNA to IND to as little as six months, without compromising quality or regulatory alignment.

Backed by over 30 years of biologics expertise, this session will highlight cutting-edge technologies, platform-driven workflows, and parallel development strategies that reduce risk and enable rapid clinical readiness. Attendees will also gain practical insights into avoiding common bottlenecks and building scalable, efficient development plans in partnership with a CDMO.